Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma.

被引：0
|
作者：
Bota, D. A.
Eroglu, Z.
Reardon, D. A.
Fu, B. D.
Norfleet, J.
Desjardins, A.
Linskey, M. E.
Peters, K.
Friedman, H. S.
Vredenburgh, J. J.
机构：
[1] Univ Calif Irvine, Med Ctr, Orange, CA USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Univ Calif Irvine, Orange, CA 92668 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2056
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Interim Analysis of a Phase I/II Study of Panobinostat in Combination with Bevacizumab for Recurrent Glioblastoma
    Lee, Eudocia
    Reardon, David
    Schiff, David
    Drappatz, Jan
    Hammond, Samantha
    Grimm, Sean
    Norden, Andrew
    Beroukhim, Rameen
    McCluskey, Christine
    Chi, Andrew
    Batchelor, Tracy
    Doherty, Lisa
    Lafrankie, Debra
    Ruland, Sandra
    Rifenburg, Jennifer
    Jacobs, Jeanne
    Smith, Katrina
    Gaffey, Sarah
    Gerard, Mary
    Snodgrass, Susan
    Raizer, Jeffrey
    Wen, Patrick
    [J]. NEUROLOGY, 2013, 80
  • [32] A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
    Sepulveda, J. M.
    Belda-Iniesta, C.
    Gil-Gil, M.
    Perez-Segura, P.
    Berrocal, A.
    Reynes, G.
    Gallego, O.
    Capellades, J.
    Ordonez, J. M.
    La Orden, B.
    Balana, C.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (09): : 743 - 750
  • [33] A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
    J. M. Sepúlveda
    C. Belda-Iniesta
    M. Gil-Gil
    P. Pérez-Segura
    A. Berrocal
    G. Reynés
    O. Gallego
    J. Capellades
    J. M. Ordoñez
    B. La Orden
    C. Balañá
    [J]. Clinical and Translational Oncology, 2015, 17 : 743 - 750
  • [34] Interim Analysis of a Phase I/II Study of Panobinostat in Combination with Bevacizumab for Recurrent Glioblastoma
    Lee, Eudocia
    Reardon, David
    Schiff, David
    Drappatz, Jan
    Hammond, Samantha
    Grimm, Sean
    Norden, Andrew
    Beroukhim, Rameen
    McCluskey, Christine
    Chi, Andrew
    Batchelor, Tracy
    Doherty, Lisa
    Lafrankie, Debra
    Ruland, Sandra
    Rifenburg, Jennifer
    Jacobs, Jeanne
    Smith, Katrina
    Gaffey, Sarah
    Gerard, Mary
    Snodgrass, Susan
    Raizer, Jeffrey
    Wen, Patrick
    [J]. NEUROLOGY, 2013, 80
  • [35] Interim analysis of a phase I/II study of panobinostat in combination with bevacizumab for recurrent glioblastoma
    Lee, Eudocia Quant
    Reardon, David A.
    Schiff, David
    Drappatz, Jan
    Muzikansky, Alona
    Hammond, Samantha
    Grimm, Sean Aaron
    Norden, Andrew David
    Beroukhim, Rameen
    McCluskey, Christine Sceppa
    Chi, Andrew S.
    Batchelor, Tracy
    Smith, Katrina H.
    Gaffey, Sarah C.
    Gerard, Mary
    Snodgrass, Susan M.
    Raizer, Jeffrey J.
    Wen, Patrick Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] A phase I clinical trial on intratumoral and intracavitary administration of ipilimumab and nivolumab in patients with recurrent glioblastoma.
    Schwarze, Julia Katharina
    Duerinck, Johnny
    Dufait, Ines
    Awada, Gil
    Klein, Samuel
    Fischbuch, Lydia
    Seynaeve, Laura
    Vaeyens, Freya
    Rogiers, Anne
    Everaert, Hendrik
    Vanbinst, Anne-Marie
    Michotte, Alex
    Neyns, Bart
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Phase I/II study of 549076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma.
    Hoang-Xuan, Khe
    Hottinger, Andreas
    Royer-Perron, Louis
    Alentorn, Agusti
    Savatovsky, Julien
    De Micheli, Rita
    Homicsko, Krisztian
    Banquet, Sebastien
    Pauly, Jeanne
    Sudey, Isabelle
    Tell, Roger
    Therasse, Patrick
    Barrie, Maryline
    Campello, Chantal
    Chinot, Olivier L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [38] PHASE II TRIAL OF ENZASTAURIN (ENZ) WITH BEVACIZUMAB (BV) IN ADULTS WITH RECURRENT GLIOBLASTOMA (GEM)
    Moustakas, Argirios
    Iwamoto, Fabio M.
    Kreisl, Teri N.
    Sul, Joohee
    Kim, Lyndon
    Butman, John
    Albert, Paul
    Fine, Howard A.
    [J]. NEURO-ONCOLOGY, 2010, 12 : 37 - 37
  • [39] A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer.
    Ling, Huichung Tina
    Muggia, Franco
    Speyer, James L.
    Curtin, John Patrick
    Blank, Stephanie V.
    Boyd, Leslie R.
    Pothuri, Bhavana
    Li, Xiaochun
    Goldberg, Judith D.
    Tiersten, Amy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Phase II study of dose-intense temozolomide in recurrent glioblastoma.
    Hammond, S.
    Norden, A. D.
    Lesser, G. J.
    Drappatz, J.
    Fadul, C. E.
    Batchelor, T.
    Quant, E. C.
    Beroukhim, R.
    Muzikansky, A.
    Ciampa, A. S.
    Doherty, L. M.
    LaFrankie, D. C.
    Ruland, S.
    Bochacki, C. A.
    Griffin, K.
    Gerard, M.
    Sceppa, C.
    Rosenfeld, M. R.
    Wen, P. Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345